

## Supplementary Online Content

Thereaux J, Lesuffleur T, Czernichow S, et al. Association between bariatric surgery and rates of continuation, discontinuation, or initiation of antidiabetes treatment 6 years later. *JAMA Surg*. Published online February 14, 2018. doi:10.1001/jamasurg.2017.6163

**eTable 1.** French Classification of Bariatric Surgery Codes and *ICD-10* Codes for Obesity

**eTable 2.** Anatomical Therapeutic Chemical (ATC) Codes for Assessment of Drug Reimbursement

**eTable 3.** Comparison of Baseline Characteristics at Time of Bariatric Surgery Between Included and Excluded Patients (No Reimbursement for Each Year During Follow-up)

**eFigure.** Flow Chart

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable 1.** French Classification of Bariatric Surgery Codes and *ICD-10* Codes for Obesity

<b>CCAM Codes</b>	<b>Category</b>
<b>HFCC003; HFCA001</b>	Gastric bypass
<b>HFMC007; HFMA009</b>	Adjustable gastric banding
<b>HFFC018; HFFA011</b>	Sleeve gastrectomy
<b>HFFC004; HFFA001; HGCC027; HGCA009</b>	Biliopancreatic diversion ± duodenal switch
<b>E66.0</b>	Obesity due to excess calories
<b>E66.1</b>	Drug-induced obesity
<b>E66.2</b>	Extreme obesity with alveolar hypoventilation
<b>E66.8</b>	Other obesity
<b>E66.9</b>	Obesity, unspecified

**eTable 2.** Anatomical Therapeutic Chemical (ATC) Codes for Assessment of Drug Reimbursement

<b>Drugs</b>	<b>ATC Codes</b>
<b>Opioids</b>	N02A
<b>Antidepressants</b>	N06A
<b>Anxiolytics and hypnotics/sedatives</b>	N05B/N05C
<b>Drugs used in diabetes</b>	A10
<b>lipid modifying agents</b>	C10

**eTable 3.** Comparison of Baseline Characteristics at Time of Bariatric Surgery Between Included and Excluded Patients (No Reimbursement for Each Year During Follow-up)\*

Characteristics	Overall Cohort N=15,650	Excluded patients N=2,609	p-values
Age (years)	38.9 (11.2)	33.5 (11.8)	<0.001
Female	13,241 (84.6)	2,068 (79.3)	<0.001
Universal health insurance coverage for patients with low income	2,418 (15.5)	537 (25.9)	<0.001
<b>BMI categories (kg/m<sup>2</sup>) †</b>			
30.0-39.9 kg/m <sup>2</sup>	4,358 (27.8)	610 (23.4)	<0.001
40.0-49.9 kg/m <sup>2</sup>	9,335 (59.6)	1,640 (62.9)	
>50.0 kg/m <sup>2</sup>	1,144 (7.3)	227 (8.7)	
Obesity, BMI unspecified	813 (5.2)	132 (5.1)	
<b>Geographic socioeconomic deprivation index</b>			
1 <sup>st</sup> quintile (less deprived)	2,940 (20.1)	377 (19.5)	<0.001
2 <sup>nd</sup> quintile	2,963 (20.2)	339 (17.5)	
3 <sup>rd</sup> quintile	2,974 (20.3)	362 (18.7)	
4 <sup>th</sup> quintile	2,912 (19.9)	403 (20.8)	
5 <sup>th</sup> quintile (most deprived)	2,851 (19.5)	452 (23.4)	
Private hospital	10,521 (67.2)	1,806 (69.2)	NS
<b>Number of bariatric procedures/year</b>			
<30	2,322 (14.8)	338 (13.0)	<0.001
30-100	5,588 (35.7)	844 (32.3)	
>100	7,740 (49.5)	1,427 (54.7)	
<b>Type of procedure</b>			
AGB	7,592 (48.5)	1,316 (50.4)	0.023
GBP	4,331 (27.7)	647 (24.8)	
SG	3,445 (22.0)	594 (22.8)	
BPD±DS	282 (1.8)	52 (2.0)	
<b>Coexisting conditions</b>			
Antihypertensive treatment	3,775 (24.1)	219 (8.4)	<0.001
Diabetes treatment	1,633 (10.4)	104 (4.0)	<0.001
Obstructive sleep apnoea syndrome treatment	4,322 (27.6)	353 (13.5)	<0.001
Lipid-lowering treatment	1,660 (10.6)	89 (3.4)	<0.001
Antidepressant treatment	2,706 (17.3)	140 (5.4)	<0.001
Anxiolytic treatment	1,646 (10.6)	146 (5.6)	<0.001
Opioid treatment	3,139 (20.1)	204 (7.8)	<0.001

\* Values are expressed as mean (SD) or number (%), as appropriate. P values were calculated using Chi-square test for categorical variables and analysis of variance for continuous variables.  
† Body-mass index is the weight in kilograms divided by the square of the height in metres.  
NS: Not significant; AGB: Adjustable gastric banding; GBP: Gastric by-pass; SG: Sleeve gastrectomy; BPD±DS: Biliopancreatic diversion± Duodenal switch.

**eFigure. Flow Chart**

BS: Bariatric Surgery; BMI: Body Mass Index; ICD: International Classification of Disease

